Medilink Announces Formal Acceptance by NMPA of Marketing Application for Tam-Peli (YL201) for Third-Line and Beyond Treatment of Nasopharyngeal Carcinoma

The special edition of Jiefang Daily praises Medilink’s innovative drug R&D achievements

MediLink Therapeutics Announces B7-H3 ADC YL201 Met Primary Endpoint in Phase 3 Nasopharyngeal Carcinoma Study

SUZHOU, China – May 29, 2026 – MediLink Therapeutics (Suzhou) Co., Ltd. today announced that tambotatug pelitecan (Tam-Peli, R&D code: YL201), its investigational B7-H3 targeted antibody-drug conjugate (ADC), has achieved positive results in the pre-specified interim analysis of the Phase 3 registrational clinical trial (TAISHAN-301) for recurrent or metastatic nasopharyngeal carcinoma (NPC). The Independent Data Monitoring Committee (IDMC) confirmed that the trial met the endpoint of confirmed objective response rate (cORR) as assessed by Blinded Independent Central Review (BICR), demonstrating a statistically significant improvement compared to chemotherapy. The second co-primary endpoint of overall survival (OS) is not yet mature. This marks the first positive Phase 3 result for any B7-H3 targeted ADC worldwide.